计算溶液所需的质量、体积或浓度。
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
货号 (SKU) | 包装规格 | 是否现货 | 价格 | 数量 |
---|---|---|---|---|
C171830-10mg |
10mg |
现货 ![]() |
| |
C171830-50mg |
50mg |
现货 ![]() |
| |
C171830-250mg |
250mg |
现货 ![]() |
| |
C171830-1g |
1g |
现货 ![]() |
|
英文别名 | (3S,11AR)-N-(2,4-difluorobenzyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide | HMS2236F06 | N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)p |
---|---|
规格或纯度 | Moligand™, ≥97% |
英文名称 | Cabotegravir |
储存温度 | -20°C储存 |
运输条件 | 超低温冰袋运输 |
作用类型 | 抑制剂 |
作用机制 | 人体免疫缺陷病毒 1 型整合酶抑制剂 |
产品介绍 |
Cabotegravir (GSK744, GSK1265744, S/GSK1265744)是一种长效HIV integrase抑制剂,作用于广泛的HIV亚型,抑制了HIV-1 integrase 催化的链转移反应的IC50为3 nM Cabotegravir is a long acting HIV-1 integrase inhibitor with action against a broad range of HIV subtypes. |
ALogP | 2.1 |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
活性类型 | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
---|
PubChem SID | 504771384 |
---|---|
分子类型 | 小分子 |
IUPAC Name | (3R,6S)-N-[(2,4-difluorophenyl)methyl]-10-hydroxy-6-methyl-8,11-dioxo-4-oxa-1,7-diazatricyclo[7.4.0.03,7]trideca-9,12-diene-12-carboxamide |
INCHI | InChI=1S/C19H17F2N3O5/c1-9-8-29-14-7-23-6-12(16(25)17(26)15(23)19(28)24(9)14)18(27)22-5-10-2-3-11(20)4-13(10)21/h2-4,6,9,14,26H,5,7-8H2,1H3,(H,22,27)/t9-,14+/m0/s1 |
InChi Key | WCWSTNLSLKSJPK-LKFCYVNXSA-N |
Canonical SMILES | CC1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O |
Isomeric SMILES | C[C@H]1CO[C@H]2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O |
PubChem CID | 54713659 |
分子量 | 405.3522 |
溶解性 | Chloroform (Slightly, Sonicated), DMSO (Slightly, Heated), Methanol (Slightly, Heated) |
---|---|
熔点 | 248-251ºC |
分子量 | 405.400 g/mol |
XLogP3 | 2.100 |
氢键供体数Hydrogen Bond Donor Count | 2 |
氢键受体数Hydrogen Bond Acceptor Count | 8 |
可旋转键计数Rotatable Bond Count | 3 |
精确质量Exact Mass | 405.114 Da |
单同位素质量Monoisotopic Mass | 405.114 Da |
拓扑极表面积Topological Polar Surface Area | 99.200 Ų |
重原子数Heavy Atom Count | 29 |
形式电荷Formal Charge | 0 |
复杂度Complexity | 814.000 |
同位素原子数Isotope Atom Count | 0 |
定义的原子立体中心计数Defined Atom Stereocenter Count | 2 |
未定义的原子立体中心计数Undefined Atom Stereocenter Count | 0 |
定义的键立体中心计数Defined Bond Stereocenter Count | 0 |
未定义的键立体中心计数Undefined Bond Stereocenter Count | 0 |
所有立体化学键的总数The total count of all stereochemical bonds | 0 |
共价键合单元计数Covalently-Bonded Unit Count | 1 |
Purity(HPLC) | 97-100(%) |
---|---|
Appearance(C171830) | White Solid |
Proton NMR spectrum | Conforms to Structure |
1. Johns BA, Kawasuji T, Weatherhead JG, Taishi T, Temelkoff DP, Yoshida H, Akiyama T, Taoda Y, Murai H, Kiyama R et al.. (2013) Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744).. J Med Chem, 56 (14): (5901-16). [PMID:23845180] [10.1021/op500134e] |